FDA Commissioner Scott Gottlieb. Photo: Drew Angerer/Getty Images

FDA Commissioner Scott Gottlieb told Axios that while he thinks the orphan drug market is too small to seriously dampen competition, he's open to changes in the law.

Details: Gottlieb's top priority is giving drugmakers an incentive to develop treatments for the rarest of diseases, or diseases that aren't getting much pharma attention.

Where it stands: Right now, part of the definition of an orphan drug is that it's intended for a patient population of less than 200,000 people. One idea would be to lower that number, meaning orphan designation goes to treatments for even rarer conditions.

  • In turn, there could be a "richer incentive" for drug companies to go after orphan approvals.
  • "For a drug that's already on the market, maybe you don't need as much incentive to study a subsequent indication," Gottlieb said. "Maybe we make the designation harder to get."
  • "I see a lot of things not getting studied or not getting into drug labels that should be. I'd like to have that clinical discussion," he added.

Go deeper: Blockbuster drugs are stacking up orphan approvals

Go deeper

31 mins ago - Health

Coronavirus cases are falling, but don't get too comfortable

Data: The COVID Tracking Project, state health departments; Map: Andrew Witherspoon, Danielle Alberti, Sara Wise/Axios

America's coronavirus outbreak is slowing down after a summer of explosive growth.

By the numbers: The U.S. is averaging roughly 52,000 new cases per day — still a lot of cases, but about 10.5% fewer than it was averaging last week.

32 mins ago - Health

We're doing a lot less coronavirus testing

Data: The COVID Tracking Project; Chart: Andrew Witherspoon/Axios

The U.S. is cutting back on coronavirus testing. Nationally, the number of tests performed each day is about 17% lower than it was at the end of July, and testing is also declining in hard-hit states.

Why it matters: This big reduction in testing has helped clear away delays that undermined the response to the pandemic. But doing fewer tests can also undermine the response to the pandemic.

Updated 3 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

  1. Global: Total confirmed cases as of 3 a.m. ET: 20,624,316 — Total deaths: 749,421— Total recoveries: 12,831,800Map.
  2. U.S.: Total confirmed cases as of 3 a.m. ET: 5,197,147 — Total deaths: 166,027 — Total recoveries: 1,714,960 — Total tests: 63,252,257Map.
  3. Politics: Pelosi says Mnuchin told her White House is "not budging" on stimulus position.
  4. Business: U.S. already feeling effects of ending unemployment benefits.
  5. Public health: U.S. records deadliest coronavirus day of the summer — America's two-sided COVID-19 response
  6. Education: New Jersey governor allows schools to reopenGallup: America's confidence in public school system jumps to highest level since 2004.